Caring for patients who are scheduled for placement of a peripherally inserted central catheter (PICC)?

Consider the ROXI-CATH study

Patients with central venous catheters are at a high risk of developing venous thromboembolism (VTE). There are limited treatment options for VTE, which may be life-threatening, and the ROXI-CATH clinical study is currently underway to investigate potential treatments that may prevent VTE from developing. Consider the ROXI-CATH study as an opportunity for your patients who have to undergo placement of a PICC to access emerging preventive treatments.

ROXI-CATH is a phase 2 clinical study for patients who require placement of a PICC line to deliver medication into their bloodstream. This study evaluates the safety and efficacy of two monoclonal antibodies for prevention of VTE after PICC placement.

ROXI-CATH will last about 130 days, including a 30-day screening period. Over the course of the study, the study treatment or placebo will be administered as a single dose IV infusion within 24 hours of PICC placement. The monoclonal antibodies [(REGN9933 and REGN7508)] investigated in this study bind to Factor XI, blocking its activity, which may reduce the risk of blood clotting. Patients will receive either one of the two treatments or a single dose of a matching placebo.

Patients are expected to participate in this study for approximately 130 days. During the study, participants will have approximately 7 study visits. Qualified participants may be reimbursed for travel to and from study visits (fuel and bus/train tickets), as well as food costs.

How can you help?

ROXI-CATH is enrolling approximately 195 people globally. The success of ROXI-CATH depends on physicians referring potential study participants. Your patients may be eligible if:

They are ≥18 years old at screening
They will undergo placement of a PICC for IV administration of clinically indicated medications
The PICC will remain in place for at least 14 days
They have an ECOG Performance Status ≤2 or equivalent functional status

The study team will check your patient’s full medical history to see if they meet all inclusion criteria and none of the exclusion criteria. Diversity in clinical studies is critical to developing better treatments – help ensure that your patients are represented.

If you have potentially eligible and interested patients, empower them with options and discuss the ROXI-CATH study. You may also contact the nearest study site to refer them.

Please note: Other protocol-defined inclusion/exclusion criteria apply.

Find a study site near you!

Your patient’s health and safety are our top priorities. We hope you value the impact of this research and will consider referring potential candidates. With your support, we hope to advance VTE research.